Neurogene Inc. (NGNE)

Neurogene Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	11.19	9.01	21.54	17.21	18.83
Research & Development	44.39	47.51	39.16	24.34	4.42
Other Operating Expenses	0	0	0	-7.83	47.72
Operating Expenses	55.58	56.52	60.7	33.73	70.96
Operating Income	-55.58	-56.52	-60.7	-33.73	-70.96
Interest Expense / Income	0.01	0	0	0	0
Other Expense / Income	-19.28	-1.33	-0.01	-0.45	-1.52
Pretax Income	-36.32	-55.19	-60.69	-33.28	-69.44
Net Income	-36.32	-55.19	-60.69	-33.28	-69.44
Shares Outstanding (Basic)	0	0	3	3	1
Shares Outstanding (Diluted)	5	0	3	3	1
Shares Change	1080.37%	-85.66%	6.21%	91.73%	14.93%
EPS (Basic)	27.76	-139.88	-22.00	-12.80	-51.40
EPS (Diluted)	2.93	-139.88	-22.00	-12.80	-51.40
Free Cash Flow	-51.74	-55.05	-50.82	-26.79	-16.27
Free Cash Flow Per Share	-105.20	-139.54	-18.47	-10.34	-12.04
EBITDA	-32.35	-51.38	-58.42	-31.46	-68.91
Depreciation & Amortization	3.96	3.81	2.28	1.82	0.53
EBIT	-36.31	-55.19	-60.69	-33.28	-69.44

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).